New! Sign up for our free email newsletter.
Science News
from research organizations

New front opens in battle against stroke

Medicinal approach cuts recurrence risk by 24 percent in stroke patients

February 25, 2016
University of South Carolina
Medical scientists have vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study, researchers show that pioglitazone, a member of the insulin-sensitizing class of medications called thiazolidinediones, reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.

Medical scientists just vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study recently published in the New England Journal of Medicine, researchers show that a drug reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.

It's an exciting result for a drug in a new class of medication now being harnessed to prevent stroke and related cardiovascular problems, says Souvik Sen, a professor of clinical neurology at the University of South Carolina School of Medicine and one of the co-authors of the study.

"Before, we had blood thinners, statins, and blood pressure medications," Sen says. Now we can top it off with this new drug, with additional 24 percent of risk reduction."

The three established approaches to stroke risk reduction have yielded significant fruit, according to Sen.

"When someone has a stroke, they will usually be placed on a blood thinner, such as aspirin or Plavix, or in some cases it would be on an anticoagulant, something like Coumadin, or warfarin. It depends on what caused the stroke," Sen says. "And if they have any indication of elevated cholesterol, or hardening of the blood vessels, they would be placed on a medicine called a statin, which has been shown to lower cholesterol as well as prevent stroke. And probably the most important medication is one for the treatment of blood pressure, which is one of the biggest risk factors for stroke."

The effectiveness of blood thinners, statins, and blood pressure management in reducing stroke risk was demonstrated through evidence-based studies, Sen says, with the three methods becoming, over the past decade or so, a standard of care for treating patients who have suffered a stroke. But there was another risk factor associated with stroke that researchers wanted to look at more carefully: insulin resistance.

Insulin resistance is an early step toward type 2 diabetes. In type 2 diabetes, the body is able to make insulin, which regulates blood sugar levels, but for reasons that remain unclear, is unable to use it as effectively as in an unaffected person. (Type 1 diabetes, once called juvenile-onset diabetes, is a horse of a different color: in that autoimmune disease, the pancreas's ability to even produce glucose-controlling insulin has been essentially eliminated.)

Researchers had shown that insulin resistance--sometimes referred to as pre-diabetes given its proximity to type 2 diabetes proper--was associated with a higher risk of stroke and heart attack. Both of those acute medical events involve a blood clot breaking free within the cardiovascular system, being carried to and becoming lodged at another site in the bloodstream, and then restricting blood flow to such a degree that tissue damage occurs, whether in the brain (stroke) or heart muscle (heart attack).

The research team set out to test pioglitazone, a drug within a class of medications (thiazolidinediones) that has been shown to help reduce insulin resistance; that is, increase insulin sensitivity. Some previous studies of drugs within this class had shown potential problems with side effects, so the team had to be careful not to enroll patients with certain risks, particularly for heart failure.

In a five-year, double-blind trial of pioglitazone versus a placebo, the team found that patients receiving the drug had 24% fewer incidents of either stroke or heart attack, as reported in the New England Journal of Medicine. Given that all of the patients involved were already getting a very high standard of care going into the trial, the level of success was surprising and should translate into further progress in reducing stroke's impact.

"It's a very positive result. We see pre-diabetes all the time in many of these patients, and before, the prevention strategy would not have been any different," Sen says. "And this medication, in addition to preventing stroke, is also preventing diabetes."

It also represents a new approach toward better understanding an ailment that disproportionately strikes and kills in Southeast for reasons that, according to Sen, are not fully accounted for.

"We are within what's called the stroke belt, and the very highest stroke rate is here in North Carolina, South Carolina, and Georgia. So we are actually called the buckle of the stroke belt--even within the stroke belt we have the highest rate," Sen says. "It is also a diabetes risk belt, a hypertension risk belt, a smoking belt, and people think that those factors are some of the reasons why the stroke belt exists, but even when you control for those factors, only 60 percent of the risk is accounted for."

"That means that a good 40 percent of the risk is unexplained, and studies like this help to move research in this area along. It's good to know that pre-diabetes is a risk factor for stroke or heart attack and that we can provide an additional method of prevention."

Story Source:

Materials provided by University of South Carolina. Original written by Steven Powell. Note: Content may be edited for style and length.

Journal Reference:

  1. Walter N. Kernan, Catherine M. Viscoli, Karen L. Furie, Lawrence H. Young, Silvio E. Inzucchi, Mark Gorman, Peter D. Guarino, Anne M. Lovejoy, Peter N. Peduzzi, Robin Conwit, Lawrence M. Brass, Gregory G. Schwartz, Harold P. Adams, Leo Berger, Antonio Carolei, Wayne Clark, Bruce Coull, Gary A. Ford, Dawn Kleindorfer, John R. O’Leary, Mark W. Parsons, Peter Ringleb, Souvik Sen, J. David Spence, David Tanne, David Wang, Toni R. Winder. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016; 160217112012002 DOI: 10.1056/NEJMoa1506930

Cite This Page:

University of South Carolina. "New front opens in battle against stroke." ScienceDaily. ScienceDaily, 25 February 2016. <>.
University of South Carolina. (2016, February 25). New front opens in battle against stroke. ScienceDaily. Retrieved July 14, 2024 from
University of South Carolina. "New front opens in battle against stroke." ScienceDaily. (accessed July 14, 2024).

Explore More

from ScienceDaily